rs140491072
Positions:
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP6BS2
The NM_000545.8(HNF1A):āc.965A>Gā(p.Tyr322Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000781 in 1,614,096 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: š 0.00038 ( 0 hom., cov: 32)
Exomes š: 0.000047 ( 0 hom. )
Consequence
HNF1A
NM_000545.8 missense
NM_000545.8 missense
Scores
9
7
2
Clinical Significance
Conservation
PhyloP100: 6.95
Genes affected
HNF1A (HGNC:11621): (HNF1 homeobox A) The protein encoded by this gene is a transcription factor required for the expression of several liver-specific genes. The encoded protein functions as a homodimer and binds to the inverted palindrome 5'-GTTAATNATTAAC-3'. Defects in this gene are a cause of maturity onset diabetes of the young type 3 (MODY3) and also can result in the appearance of hepatic adenomas. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Apr 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -5 ACMG points.
BP6
Variant 12-120996271-A-G is Benign according to our data. Variant chr12-120996271-A-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 36835.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=4, Uncertain_significance=1, not_provided=1, Benign=1}.
BS2
High AC in GnomAd4 at 58 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HNF1A | NM_000545.8 | c.965A>G | p.Tyr322Cys | missense_variant | 5/10 | ENST00000257555.11 | NP_000536.6 | |
HNF1A | NM_001306179.2 | c.965A>G | p.Tyr322Cys | missense_variant | 5/10 | NP_001293108.2 | ||
HNF1A | NM_001406915.1 | c.965A>G | p.Tyr322Cys | missense_variant | 5/9 | NP_001393844.1 | ||
HNF1A | XM_024449168.2 | c.965A>G | p.Tyr322Cys | missense_variant | 5/9 | XP_024304936.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HNF1A | ENST00000257555.11 | c.965A>G | p.Tyr322Cys | missense_variant | 5/10 | 1 | NM_000545.8 | ENSP00000257555.5 |
Frequencies
GnomAD3 genomes AF: 0.000381 AC: 58AN: 152156Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
58
AN:
152156
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000111 AC: 28AN: 251394Hom.: 0 AF XY: 0.0000662 AC XY: 9AN XY: 135890
GnomAD3 exomes
AF:
AC:
28
AN:
251394
Hom.:
AF XY:
AC XY:
9
AN XY:
135890
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000465 AC: 68AN: 1461822Hom.: 0 Cov.: 35 AF XY: 0.0000413 AC XY: 30AN XY: 727206
GnomAD4 exome
AF:
AC:
68
AN:
1461822
Hom.:
Cov.:
35
AF XY:
AC XY:
30
AN XY:
727206
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000381 AC: 58AN: 152274Hom.: 0 Cov.: 32 AF XY: 0.000269 AC XY: 20AN XY: 74442
GnomAD4 genome
AF:
AC:
58
AN:
152274
Hom.:
Cov.:
32
AF XY:
AC XY:
20
AN XY:
74442
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
8
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
16
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:5Other:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not specified Benign:3Other:1
Likely benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 06, 2020 | The p.Tyr322Cys variant in HNF1A is classified as likely benign because it has been identified in 0.2% (40/24952) of African chromosomes by gnomAD (http://gnomad.broadinstitute.org). ACMG/AMP Criteria applied: BS1. - |
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jul 02, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 08, 2022 | Variant summary: HNF1A c.965A>G (p.Tyr322Cys) results in a non-conservative amino acid change located in the Hepatocyte nuclear factor 1, beta isoform, C-terminal domain (IPR006897) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00011 in 251994 control chromosomes, predominantly at a frequency of 0.0017 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 68-fold of the estimated maximal expected allele frequency for a pathogenic variant in HNF1A causing Maturity Onset Diabetes Of The Young 3 phenotype (2.5e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. c.965A>G has been reported in the literature in individuals affected with Maturity Onset Diabetes Of The Young 3 (examples: Bellanne-Chantelot_2008, Flannick_2013, Pihoker_2013, Althari_2020) but it was also reported in multiple controls/unaffected individuals (Flannick_2013, Althari_2020). These reports do not provide unequivocal conclusions about association of the variant with Maturity Onset Diabetes Of The Young 3. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 30%-50% of normal transcriptional activity (Najmi_2017). Recently, the authors of this functional study re-classified the variant as likely benign utilizing multidimensional functional data and variant occurrences in patients and controls (Althari_2020). A ClinVar submitter (evaluation after 2014) cites the variant as likely benign, while two other ClinVar submitters (evaluation after 2014) cite it as uncertain significance. Based on the evidence outlined above, the variant was classified as likely benign. - |
Monogenic diabetes Uncertain:1
Uncertain significance, criteria provided, single submitter | research | Personalized Diabetes Medicine Program, University of Maryland School of Medicine | Jan 26, 2018 | ACMG criteria: PP3, BS2(T2DM 6 cases and 4 controls); (PP5 LabCorp called Likely Pathogenic[based on two pts in Bellanne-Chantelot C. et al, Diabetes 2008]); (functional studies suggest impact[abstract by Laeya Najmi at http://www.uib.no/en/clin2/83289/midway-evaluation-laeya-abdoli-najmi])=VUS - |
HNF1A-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 10, 2024 | The HNF1A c.965A>G variant is predicted to result in the amino acid substitution p.Tyr322Cys. This variant has been reported in maturity onset diabetes of the young (MODY) patients and studies of diabetes in the general population (Bellanne-Chantelot et al. 2008. PubMed ID: 18003757; Najmi et al. 2017. PubMed ID: 27899486; Flannick et al. 2013. PubMed ID: 24097065). In Najmi et al. study, functional evaluation showed that this substitution affected transcriptional activity to a certain extent, but not as significantly as well-established pathogenic missense HNF1A variants. Importantly, the minor allele frequency of this variant reaches ~0.16% in the African population, which is probably too high for this variant to be a primary cause of dominant monogenic diabetes Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 24, 2023 | - - |
Maturity-onset diabetes of the young type 3 Benign:1
Benign, criteria provided, single submitter | clinical testing | Mendelics | Aug 22, 2023 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Pathogenic
.;D;D;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Uncertain
D;D;D;D
MetaSVM
Pathogenic
D
PrimateAI
Pathogenic
T
PROVEAN
Pathogenic
D;.;D;D
REVEL
Pathogenic
Sift
Uncertain
D;.;D;D
Sift4G
Uncertain
D;D;D;D
Polyphen
1.0
.;.;.;D
Vest4
MVP
MPC
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at